PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. (1st January 2020)
- Record Type:
- Journal Article
- Title:
- PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. (1st January 2020)
- Main Title:
- PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
- Authors:
- Pico de Coaña, Yago
Wolodarski, Maria
van der Haar Àvila, Irene
Nakajima, Takahiro
Rentouli, Stamatina
Lundqvist, Andreas
Masucci, Giuseppe
Hansson, Johan
Kiessling, Rolf - Abstract:
- ABSTRACT: Blockade of the PD-1 receptor has revolutionized the treatment of metastatic melanoma, with significant increases in overall survival (OS) and a dramatic improvement in patient quality of life. Despite the success of this approach, the number of benefitting patients is limited and there is a need for predictive biomarkers as well as a deeper mechanistic analysis of the cellular populations involved in clinical responses. With the aim to find predictive biomarkers for PD-1 checkpoint blockade, an in-depth immune monitoring study was conducted in 36 advanced melanoma patients receiving pembrolizumab or nivolumab treatment at Karolinska University Hospital. Blood samples were collected before treatment and before administration of the second and fourth doses. Peripheral blood mononuclear cells were isolated and stained for flow cytometric analysis within 2 h of sample collection. Overall survival and progression-free survival (PFS) were inversely correlated with CD69 expression NK cells. In the myeloid compartment, high frequencies of non-classical monocytes and low frequencies of monocytic myeloid derived suppressor cells (MoMDSCs) correlated with response rates and OS. A deeper characterization of monocytic subsets showed that PD-L1 expression in MDSCs, non-classical and intermediate monocytes was significantly increased in patients with shorter PFS in addition to correlating inversely with OS. Our results suggest that cellular populations other than T cells can beABSTRACT: Blockade of the PD-1 receptor has revolutionized the treatment of metastatic melanoma, with significant increases in overall survival (OS) and a dramatic improvement in patient quality of life. Despite the success of this approach, the number of benefitting patients is limited and there is a need for predictive biomarkers as well as a deeper mechanistic analysis of the cellular populations involved in clinical responses. With the aim to find predictive biomarkers for PD-1 checkpoint blockade, an in-depth immune monitoring study was conducted in 36 advanced melanoma patients receiving pembrolizumab or nivolumab treatment at Karolinska University Hospital. Blood samples were collected before treatment and before administration of the second and fourth doses. Peripheral blood mononuclear cells were isolated and stained for flow cytometric analysis within 2 h of sample collection. Overall survival and progression-free survival (PFS) were inversely correlated with CD69 expression NK cells. In the myeloid compartment, high frequencies of non-classical monocytes and low frequencies of monocytic myeloid derived suppressor cells (MoMDSCs) correlated with response rates and OS. A deeper characterization of monocytic subsets showed that PD-L1 expression in MDSCs, non-classical and intermediate monocytes was significantly increased in patients with shorter PFS in addition to correlating inversely with OS. Our results suggest that cellular populations other than T cells can be critical in the outcome of PD-1 blockade treatment. Specifically, the frequencies of activated NK cells and monocytic subsets are inversely correlated with survival and clinical benefit, suggesting that their role as predictive biomarkers should be further evaluated. … (more)
- Is Part Of:
- Oncoimmunology. Volume 9:Number 1(2020)
- Journal:
- Oncoimmunology
- Issue:
- Volume 9:Number 1(2020)
- Issue Display:
- Volume 9, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 9
- Issue:
- 1
- Issue Sort Value:
- 2020-0009-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-01-01
- Subjects:
- Melanoma -- immune checkpoint inhibitors -- MDSCs -- NK cells -- predictive biomarkers
Tumors -- Immunological aspects -- Periodicals
Neoplasms -- therapy -- Periodicals
Immunotherapy -- Periodicals
616.994 - Journal URLs:
- http://www.landesbioscience.com/journals/oncoimmunology/ ↗
http://www.tandfonline.com/toc/koni20/current ↗
http://www.tandf.co.uk/journals/ ↗ - DOI:
- 10.1080/2162402X.2020.1786888 ↗
- Languages:
- English
- ISSNs:
- 2162-402X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26300.xml